Company: RGNT
Filing Date: 2025-07-07
Form Type: F-1/A
Source: 0001213900-25-061821
Chunk: 190

Company: REGENTIS BIOMATERIALS LTD.
Filing Date: 2025-07-07
Form: F-1/A
Chunk 190
---
 include individuals who hold more than 5% interest.           
 Medica III Management L.P., an entity held 50% by Dr. Ehud Geller and 50% by Batsheva Elran, is the managing entity of Medica III            
 Fund. The principal business address of Medica III Investment is 60C Medinat Hayehudim, Herzliya, 4676670, Israel.                           |

| (7) | Consists of (1) 270,473                                                                                                              
 Ordinary Shares held by SCP Vitalife Partners II L.P., and (2) 130,465 Ordinary Shares held by SCP Vitalife Partners (Israel) II     
 L.P. Mr. Jeff Dykan. is the general partner of the foregoing entities, and, as such, holds share voting and dispositive power over   
 the shares held by the foregoing entities. The principal business address of SCP Vitalife Partners II L.P., is Messrs. Churchill     
 and Weisman, 5 Great Valley Parkway, Suite 210, Malvern, Pennsylvania 19355. The principal business address of SCP Vitalife Partners 
 (Israel) II L.P. is 15 Hatidhar, P.O. Box 2138, Raanana, Tel Aviv 4366517, Israel.                                                   |
| (8) | Consists of options to                                                                                                               
 purchase up to 37,500 Ordinary Shares.                                                                                               |

<div align='center'>113

CERTAIN RELATIONSHIPS AND RELATED PARTY TRANSACTIONS</div>

The following is a description
of the material terms of those transactions with related parties to which we are party.

Convertible Loans

In September of 2021, we
entered into several convertible loan agreements, or the 2021 CLAs, pursuant to which we obtained a convertible loan in the aggregate
amount of $835,000. In connection with the 2021 CLAs, the lenders were granted warrants to purchase shares of the Company of the same
class of the conversion securities. Effective as of March 11, 2024, the 2021 CLAs were converted into 88,385 Ordinary Shares and the
warrants granted thereunder expired in full in December 2023.

Between August 2020 and February
2021, we entered into the 2020 CLAs, pursuant to which we obtained a convertible loan in the aggregate amount of $900,000. The 2020 CLAs
have been extended until August 31,